Two years ago, Zoetis traded at roughly 35 times its annual earnings. Today it trades at roughly 12 times. The revenue line has kept growing. The margin line has kept growing. Those two facts should not coexist, and the gap between them is the whole story.
Zoetis makes medicines for animals, which sounds like a niche until you consider that almost every pet owner, farmer, and livestock operation in the developed world buys its products. The company was spun out of Pfizer in 2013 and spent the next decade becoming the dominant name in animal health, growing revenue every single year and expanding what it kept from each dollar of sales. Then, in the spring of 2026, something broke. Not the business exactly, but the market’s confidence in one part of it, and the stock got cut in half.
First, the shape of it
The filed numbers show a company that has grown revenue every year since 2020 and now keeps more profit from every dollar of sales than it ever has. The stock is priced at a multiple, the price tag per dollar of annual profit, that sits in the bottom few percent of its own decade-long history. The open question is whether the current stumble in one product category is a permanent reset or a temporary bruise. Those two readings cannot both be right, and that disagreement is the story.
How It Got Here
For most of its public life, Zoetis was a reliable compounder: a business that grew steadily, reinvested in its pipeline, and rewarded patience. A large diagnostics acquisition in 2018 broadened the business beyond medicines. The dermatology franchise, built around drugs that treat itchy skin conditions in dogs and cats, became a genuine blockbuster. By 2023, the stock carried a premium multiple because the market believed the growth was durable.
Then competition arrived. New entrants in the companion animal dermatology market began offering promotional incentives to clinics, pulling prescriptions away from Zoetis’s flagship products. Clinic visits softened as pet owners, squeezed by broader cost pressures, deferred non-urgent veterinary care. On May 7, 2026, Zoetis reported a miss on Q1 2026 earnings and cut its full-year guidance. The stock fell more than a fifth in a single session. By August, it had lost half its value from its 52-week high.
What the Filings Actually Show
Start with the long view. The 10-K for fiscal year 2025 shows total revenue of $9.5 billion, up meaningfully from 2020. That is five consecutive years of growth. Net margin, the share of each revenue dollar that survives all costs and taxes, rose from the low-to-mid twenties in 2020 to 28.2% in 2025. The business was not just getting bigger; it was getting more efficient at the same time.
The Q2 2026 10-Q is where the trouble shows up in the numbers. U.S. revenue fell in the quarter, dragged down by a sharp drop in companion animal sales. Key dermatology products fell 16% globally, according to the Q2 2026 earnings release. Management described a “more pressured Companion Animal market,” citing lower clinic visits and pet owner price sensitivity. International held up better, rising solidly, but it was not enough to offset the domestic slide.
The saving grace, and it matters, is that the gross margin held. Adjusted gross margin for Q2 2026 was nearly 73 cents on every dollar of sales, down only fractionally from a year earlier. A gross margin is what remains after the direct cost of making the product; at that level, Zoetis still has an unusually wide buffer to absorb competition. A typical pharmaceutical company would envy that number.
The Guidance Cut and What It Signals
The most consequential filed fact is the guidance revision. The 2025 annual report had management projecting 2026 revenue in the high nines, approaching ten billion dollars. The Q2 2026 update brought that down by roughly $700 million at the midpoint and flipped the organic growth outlook from a modest increase to a modest decline. Adjusted earnings per share guidance dropped by roughly 70 cents at the midpoint.
That is a meaningful reset. But notice what it does not say: it does not say the business is shrinking into irrelevance. Even at the high end of the new guidance, 2026 revenue would be only modestly above 2024’s total, and the low end would fall slightly below it. The company is guiding for a pause, not a collapse.
The debt picture deserves a clear look. As of the end of fiscal 2025, total debt stood at $9.23 billion, roughly equal to a full year of revenue. Think of it as a household that earns $80,000 a year carrying $80,000 on the card: manageable if income stays steady, uncomfortable if it falls. With operating margin near 38% and gross margin close to 73%, the cash generation to service that debt has not disappeared, but the cushion is thinner than the headline debt figure suggests.
The Pipeline as a Counterweight
Zoetis spent nearly $700 million on research and development in 2025, as reported in the 2025 10-K, about seven cents of every revenue dollar plowed back into future products. The pipeline that spending is funding includes some concrete near-term items: Lenivia and Portela, long-acting monoclonal antibody therapies for arthritis pain in dogs and cats, launched in Canada and the EU by July 2026 and approved in Great Britain. Simparica Trio received U.S. FDA Emergency Use Authorization in August 2026 for a screwworm outbreak response. A next-generation version of Cytopoint, the flagship dermatology product, is anticipated for 2026 approval.
Whether these launches can refill what the dermatology competition has taken is the question the filed numbers cannot yet answer. The data does not exist. We say so plainly.
The Math and the Mood
Our data shows Zoetis trading at a P/E of 11.9 times trailing earnings, against a decade median of 37.31 times. The P/S ratio, the price tag per dollar of annual sales, sits at a similarly depressed level relative to its own history. On both gauges, the stock has rarely been this cheap relative to its own decade-long history.
The math, meaning what the filed fundamentals describe, is a business with expanding margins, a wide gross margin buffer, a growing pipeline, and a temporary revenue stumble concentrated in one competitive segment. The mood, meaning what the market is currently paying, prices in something closer to permanent impairment. William Blair downgraded Zoetis to Market Perform on August 6, 2026, and firms including Stifel Nicolaus, UBS, and Citi cut their price targets through July and August. Stifel’s target sits barely above where the stock already trades, suggesting those analysts see limited near-term recovery.
The tension is real. A business earning more per dollar of sales each year, priced as if that improvement is over. Both readings are grounded in evidence. They cannot both be right.
Reading the Numbers
- Net margin, 28.2% in FY2025 (from the 2025 10-K): of every dollar Zoetis collected in revenue, it kept 28 cents as profit after all costs. A decade ago that figure was closer to 20 cents. If a small restaurant earned $500,000 in sales and kept $141,000 as profit, that would be the equivalent. The trend upward matters because it means the business is not just growing, it is becoming more efficient as it grows.
- P/E of 11.9 versus decade median of 37.31 (our data): the P/E is the price a buyer pays for each dollar of annual profit. At 37 times, a buyer paid $37 for every $1 of earnings. At 12 times, the same buyer pays $12. The gap implies the market now expects either much lower future profits or a permanently lower valuation standard for this kind of business. History says both cannot be assumed without evidence.
- Dermatology revenue down 16% globally in Q2 2026 (from the Q2 2026 10-Q): if a product line was generating $100 million per quarter, a 16% drop takes it to $84 million. Multiplied across four quarters, that is a meaningful hole in annual revenue. The question is whether new products fill it, and that answer is not yet in any filing.
- Total debt of $9.23 billion against $9.5 billion in annual revenue (from the 2025 10-K): scale-shrunk to kitchen-table size, a household earning $95,000 a year with $92,300 in debt. Serviceable, but it leaves less room to maneuver if revenue keeps sliding.
Reading the numbers
- Net margin of 28.2% in FY2025: net margin is the share of each revenue dollar a company keeps after paying every cost, manufacturing, salaries, interest on debt, taxes, everything. At 28.2%, Zoetis keeps nearly 28 cents from every dollar it collects. That figure has risen steadily from roughly 20 cents a decade ago, which means the business is not just bigger but structurally more profitable. In this story it matters because it shows the underlying engine is still running well even as one product line stumbles.
- P/E of 11.9 versus a decade median of 37.31: the price-to-earnings ratio is simply what a buyer pays today for each dollar of annual profit. At 37 times, where Zoetis spent most of the past decade, a buyer paid $37 per $1 of earnings. At 11.9 times, that same dollar of earnings costs $12. The gap is the central tension of the article: either the market has spotted something the income statement has not yet shown, or the stock is priced for a permanent decline that the filed numbers do not yet support. Both cannot be true.
- Dermatology revenue down 16% globally in Q2 2026: this is the number that broke the stock. A 16% drop in a product category that had been a key growth driver punched a visible hole in quarterly revenue and forced management to cut full-year guidance by roughly $700 million at the midpoint. It moves the story because it is the single data point the market is extrapolating forward, the question the rest of the article turns on is whether that extrapolation is correct or overdone.
For the standing yardsticks on Zoetis: the price tag, the filed record, and the four gauges, refreshed with each edition, see the BullScope Evidence Sheet: Zoetis.
Sources
- Zoetis 10-Q, quarter ended June 30, 2026 (SEC EDGAR)
- Zoetis 10-K, fiscal year ended December 31, 2025 (SEC EDGAR)
- Zoetis Q2 2026 earnings release (investor.zoetis.com)
- Zoetis Q2 2026 slides: mixed results and guidance cut (Investing.com)
- Zoetis Q2 2026 slides: livestock gains, companion animal weakness (Investing.com)
- William Blair Market Perform rating, August 6, 2026 (MarketBeat)
- Zoetis agreement to acquire Neogen animal genomics business (investor.zoetis.com)
